Publications & Presentations

The information in our publications and presentations should be considered accurate only as of the date of the publications or presentations. We disclaim any obligation to supplement or update the information in these publications and presentations.

To learn more about our innovative technology:

Publications Presentations

Dihydroergotamine (DHE) – Then and Now: A Narrative Review

November 17, 2019 Stephen D. Silberstein, MD; Stephen B. Shrewsbury, MBChB; John Hoekman, PhD Objective: To provide a narrative review of clinical development programs for non-oral, non-injectable formulations of dihydroergotamine (DHE) for the treatment of migraine. Background: Dihydroergotamine was one…

STOP 101: A Phase 1, Randomized, Open‐Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in Healthy Adult Subjects

January 2019 - INP104 met the predefined statistical criteria for comparative bioavailability with IV DHE and Migranal. The shorter time to reach Cmax and at 4 times the plasma concentration of DHE in comparison to Migranal combined with a favorable…

2 3